本报告期内，公司深耕分析色谱与工业纯化两大核心领域，以技术创新为驱动，持续深化产品性能优化 与核心技术自主研发。在此基础上，公司把握国产替代战略窗口期，一方面积极开拓增量客户项目，扩 大市场覆盖边界；另一方面稳步推进存量客户已导入项目的复购转化，深化客户合作粘性。双轮驱动 下，公司经营规模实现进一步扩张，盈利能力保持稳定向上态势。 格隆汇10月15日丨赛分科技(688758.SH)公布，预计公司2025年前三季度实现营业收入2.95亿元到3.17亿 元，同比增长35%到45%。实现归属于母公司所有者的净利润为9,000.00万元到9,800.00万元，同比增长 65%到80%。实现归属于母公司所有者扣除非经常性损益后的净利润为8,100.00万元到8,900.00万元，同 比增长50%到65%。 ...

南财智讯10月15日电，赛分科技发布三季度业绩预告，预计前三季度归属于上市公司股东的净利润为 9,000.00万元—9,800.00万元，同比预增65%—80%；预计前三季度归属于上市公司股东的扣除非经常性 损益的净利润为8,100.00万元—8,900.00万元，同比预增50%—65%。变动原因：本报告期内，公司深耕 分析色谱与工业纯化两大核心领域，以技术创新为驱动，持续深化产品性能优化与核心技术自主研发。 在此基础上，公司把握国产替代战略窗口期，一方面积极开拓增量客户项目，扩大市场覆盖边界；另一 方面稳步推进存量客户已导入项目的复购转化，深化客户合作粘性。双轮驱动下，公司经营规模实现进 一步扩张，盈利能力保持稳定向上态势。 ...

10月13日，赛分科技跌1.14%，成交额2988.68万元。两融数据显示，当日赛分科技获融资买入额235.74 万元，融资偿还146.11万元，融资净买入89.63万元。截至10月13日，赛分科技融资融券余额合计 4380.37万元。 融资方面，赛分科技当日融资买入235.74万元。当前融资余额4380.37万元，占流通市值的5.96%。 融券方面，赛分科技10月13日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元。 机构持仓方面，截止2025年6月30日，赛分科技十大流通股东中，南方科创板3年定开混合（506000）位 居第一大流通股东，持股79.11万股，相比上期减少89.36万股。银河医药混合A（011335）退出十大流 通股东之列。 责任编辑：小浪快报 资料显示，苏州赛分科技股份有限公司位于中国(江苏)自由贸易试验区苏州片区苏州工业园区集贤街11 号，成立日期2009年3月16日，上市日期2025年1月10日，公司主营业务涉及研发和生产用于药物分析检 测和分离纯化的液相色谱材料。主营业务收入构成为：工业纯化板块33.10%，工业 ...

Core Viewpoint - The announcement from Saifen Technology indicates that core technical personnel Yang Ke has officially retired due to reaching the legal retirement age, and he will no longer be recognized as a core technical staff member or hold any position within the company [1] Company Summary - Yang Ke's retirement marks a significant change in the company's technical leadership, as he was previously recognized as a core technical personnel [1] - The company will need to address the potential impact of this leadership change on its ongoing projects and technological development [1]

中信证券股份有限公司 关于苏州赛分科技股份有限公司 核心技术人员离职的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）作为苏州赛分 科技股份有限公司（以下简称"赛分科技"、"公司"）首次公开发行股票并在科 创板上市的保荐人，根据《首次公开发行股票注册管理办法》《上海证券交易所 科创板股票上市规则》等有关法律法规和规范性文件的要求，对公司核心技术人 员离职事项进行了专项核查，具体情况及核查意见如下： 一、杨克先生离职的具体情况 公司核心技术人员杨克先生因达到法定退休年龄，于近日正式退休，公司不 再认定其为核心技术人员，且杨克先生不再担任公司任何职务。 （一）核心技术人员的具体情况 （三）竞业限制及保密情况 根据公司与杨克先生签署的《竞业限制及保密协议》，双方对保密内容、竞 业限制等事项进行了明确的约定。截至本核查意见出具之日，公司未发现杨克先 生有违反《竞业限制及保密协议》的情形。 二、核心技术人员离职对公司的影响 公司高度重视研发工作，不断完善研发体系建设，研发运营团队结构完整， 研发平台各部门各司其职，公司的技术研发与生产运营工作均正常开展，不存在 对特定核心技术人员单一依赖的情形。目前， ...

证券代码：688758 证券简称：赛分科技 公告编号：2025-036 重要内容提示： 一、杨克先生离职的具体情况 公司核心技术人员杨克先生因达到法定退休年龄，于近日正式退休，公司不 再认定其为核心技术人员，且杨克先生不再担任公司任何职务。公司及董事会对 杨克先生任职期间为公司发展所做出的努力和贡献表示衷心感谢。 1、核心技术人员的具体情况 杨克，赛分科技研究院士，美国布兰迪斯大学（Brandeis）博士，麻省理工 学院（MIT）博士后。1995 年至 2008 年，先后供职于美国 Memorial Sloan-Kettering Cancer Center，Pharmacoepeia, Inc.，Message Pharmaceutical, Inc. 和 Astrazeneca 苏州赛分科技股份有限公司 关于核心技术人员离职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 苏州赛分科技股份有限公司（以下简称"赛分科技"或"公司"）核心 技术人员杨克先生因达到法定退休年龄，于近日正式退休离职，公司不 再认定其为核心 ...

Group 1 - Core technical personnel Yang Ke has officially retired due to reaching the legal retirement age and will no longer hold any position in the company [1] - As of the report, the market capitalization of the company is 7.7 billion yuan [1] Group 2 - For the fiscal year 2024, the revenue composition of the company is as follows: drug analysis accounts for 40.2%, antibody drugs for 20.85%, insulin/peptide/GLP-1 for 18.18%, recombinant proteins for 13.73%, and others for 6.6% [1]

Group 1 - The core viewpoint of the news is that Sai Fen Technology experienced a decline in stock price and negative net financing on September 22, 2023, indicating potential liquidity issues [1] - On September 22, 2023, Sai Fen Technology's stock price fell by 1.75%, with a trading volume of 34.52 million yuan. The net financing amount was -5.14 million yuan, with a total financing and margin balance of 41.92 million yuan [1] - The financing buy-in amount for Sai Fen Technology on the same day was 3.58 million yuan, while the financing repayment was 8.72 million yuan, leading to a current financing balance that constitutes 5.48% of the circulating market value [1] Group 2 - Sai Fen Technology, established on March 16, 2009, is located in the Suzhou Industrial Park and specializes in the research and production of liquid chromatography materials for drug analysis and purification [2] - For the period from January to June 2025, Sai Fen Technology achieved operating revenue of 183 million yuan, representing a year-on-year growth of 19.76%, and a net profit attributable to shareholders of 53.66 million yuan, up 40.91% year-on-year [2] - The company's revenue composition includes 33.10% from industrial purification, 32.65% from industrial purification fillers, and 16.73% from analytical chromatography, among other segments [2] Group 3 - As of June 30, 2025, Sai Fen Technology had 10,500 shareholders, a decrease of 4.63% from the previous period, with an average of 3,779 circulating shares per person, an increase of 4.86% [2] - The company has distributed a total of 27.90 million yuan in dividends since its A-share listing [3] - The largest circulating shareholder as of June 30, 2025, is the Southern Science and Technology Innovation Board 3-Year Open Mixed Fund, holding 791,100 shares, a decrease of 893,600 shares from the previous period [3]

Company Overview - Suzhou Saifen Technology Co., Ltd. is located in the Suzhou Industrial Park, Jiangsu Free Trade Zone, and was established on March 16, 2009. The company is set to be listed on January 10, 2025. Its main business involves the research and production of liquid chromatography materials used for drug analysis and purification [2]. Financial Performance - For the period from January to June 2025, the company achieved operating revenue of 183 million yuan, representing a year-on-year growth of 19.76%. The net profit attributable to the parent company was 53.66 million yuan, reflecting a year-on-year increase of 40.91% [2]. Business Segmentation - The revenue composition of Saifen Technology is as follows: Industrial purification segment accounts for 33.10%, industrial purification fillers 32.65%, analytical chromatography segment 16.73%, analytical chromatography columns 13.31%, analytical chromatography fillers 3.13%, and other segments contribute minor percentages [2]. Shareholder Information - As of June 30, 2025, the number of shareholders of Saifen Technology was 10,500, a decrease of 4.63% from the previous period. The average circulating shares per person increased by 4.86% to 3,779 shares [2]. Dividend Distribution - The company has cumulatively distributed dividends amounting to 27.90 million yuan since its A-share listing [3]. Institutional Holdings - As of June 30, 2025, the largest circulating shareholder is the Southern Science and Technology Innovation Board 3-Year Open Mixed Fund (506000), holding 791,100 shares, which is a decrease of 893,600 shares compared to the previous period. The Galaxy Medical Mixed A Fund (011335) has exited the top ten circulating shareholders list [3]. Market Activity - On September 17, 2023, Saifen Technology's stock rose by 0.33%, with a trading volume of 45.03 million yuan. The financing buy-in amount for that day was 3.22 million yuan, while the financing repayment was 3.51 million yuan, resulting in a net financing buy-in of -0.29 million yuan. The total financing and securities lending balance as of September 17, 2023, was 43.54 million yuan [1].

Core Points - The company announced a cash dividend of CNY 0.026 per share for the first half of 2025, totaling CNY 10,828,066.18 for all shareholders [2][4]. Distribution Plan - The dividend distribution plan was authorized by the shareholders' meeting on May 20, 2025, and approved by the board on August 16, 2025 [2][3]. - The distribution is based on a total share capital of 416,464,084 shares [4]. Implementation Details - Shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date will receive the dividend [3][5]. - The cash dividend will be distributed through the clearing system of China Securities Depository and Clearing Corporation Limited [5]. Taxation Information - For individual shareholders holding unrestricted shares for over one year, the dividend is exempt from personal income tax, resulting in a net cash dividend of CNY 0.026 per share [8]. - For shares held for less than one year, the tax will be calculated upon transfer, with a potential tax rate of 20% for shares held for one month or less [9]. - For qualified foreign institutional investors (QFII), a 10% withholding tax will apply, leading to a net cash dividend of CNY 0.0234 per share [10].